Skip to main content

DMAT

MaterialsMilan, Italy; Cambridge, MA, USAFounded 2022· One of 961 Materials companies tracked by AMPulse

Develops sustainable, self-healing concrete and mortar technologies inspired by ancient Roman techniques to reduce CO2 emissions and extend material lifespan.

CEO / Founder
Paolo Sabatini
Team Size
1-10
Stage
Active
Total Funding
$8.3M
Latest Round
Seed
Key Investors
Primo Capital, Safar Partners, PeopleFund, Deep Future, Corbites

Technology & Products

Key Products

Proprietary mix designs; Self-healing fillers

Technological Advantage

60% CO2 reduction; 2x lifespan; no retrofitting costs; enhances carbonation resistance.

Differentiation

Value Proposition

Reduces CO2 emissions by up to 60% and doubles material lifespan by self-healing cracks <1mm, eliminating retrofitting costs for producers.

How They Differentiate

Uses Roman-inspired bio-mimicry for self-healing, achieving significantly higher CO2 reduction (60%) and lifespan extension compared to standard concrete. Spun out of the Massachusetts Institute of Technology (MIT).

Market & Competition

Target Customers

European concrete manufacturers, prefabrication plants, construction companies.

Industry Verticals

Building; Construction; Infrastructure

Competitors

Adaptavate, Neustark, CUT

Growth & Milestones

Growth Metrics

60% CO2 reduction; doubles concrete lifespan; targets 180,000 producers

Major Milestones

Market presence in Italy/Switzerland; US production activation planned; Raised $4.5M for commercialization

Notable Customers

FEDRO (Federal Roads Office of Switzerland); Crezza Srl; Infrastructure developers; Precast concrete producers; Public agencies

https://dmat.co

Why this company matters

DMAT develops self-healing concrete and mortar technologies that mimic ancient Roman techniques to reduce CO2 emissions and extend material lifespan. The company targets the building, construction, and infrastructure sectors with a value proposition centered on eliminating retrofitting costs and improving durability. Its bio-inspired lime clinkers automatically repair cracks smaller than 1mm, a capability that differentiates it from standard concrete and from competitors such as Adaptavate, Neustark, and CUT.

The core technology involves proprietary mix designs and self-healing fillers that enhance carbonation resistance. DMAT claims a 60% reduction in CO2 emissions and a doubling of concrete lifespan compared to conventional alternatives. The company holds at least two patent applications related to self-healing cementitious materials and their production methods. DMAT was founded in 2022 and is headquartered in Milan, Italy, with an additional office in Cambridge, Massachusetts, reflecting its roots in MIT research.

Target customers include European concrete manufacturers, prefabrication plants, and construction companies. Named clients include FEDRO (the Federal Roads Office of Switzerland) and Crezza Srl, as well as infrastructure developers and public agencies. The company has raised $8.3 million in total funding from investors including Primo Capital, Safar Partners, PeopleFund, Deep Future, and Corbites. A $4.5 million raise was specifically allocated to commercialization efforts. DMAT currently has a team of 1-10 employees and is led by CEO Paolo Sabatini, who co-founded the company from MIT research.

The company's strategic moat lies in its bio-mimetic approach to self-healing, which is difficult to replicate with conventional cement chemistry. However, scaling from lab to mass production and convincing risk-averse construction supply chains to adopt a novel additive remain open challenges. DMAT targets 180,000 producers across Europe and plans to activate US production, but execution will depend on cost parity and regulatory acceptance in a conservative industry.